N-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-[1,3,5]triazine-2,4-diamine | 652153-59-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: N-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-[1,3,5]triazine-2,4-diamine
• 英文别名: 1,3,5-Triazine-2,4-diamine, N-(3-chlorophenyl)-6-(2-chloro-4-pyridinyl)-；2-N-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-1,3,5-triazine-2,4-diamine
• CAS: 652153-59-8
• 化学式: C₁₄H₁₀Cl₂N₆
• 分子量: 333.18
• InChiKey: HDWNCWZLESIZIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-[1,3,5]triazine-2,4-diamine 、 3-氨基-1-丙醇 反应 96.0h， 以30 mg的产率得到3-((4-(4-amino-6-((3-chlorophenyl)amino)-1,3,5-triazin-2-yl)-2-pyridinyl)amino)-1-propanol
  参考文献：
  名称：

  [EN] SUBSTITUTED TRIAZINE KINASE INHIBITORS
  [FR] INHIBITEURS DES KINASES A BASE DE TRIAZINE SUBSTITUEE

  摘要：

  本发明提供了替代的1,3,5-三嗪化合物作为激酶抑制剂，并提供了一种治疗或改善激酶介导的疾病的方法。

  公开号：

  WO2004009562A1
• 作为产物：
  描述：

  2-氯吡啶-4-甲酰氯 、 1-(3-氯苯基)双胍 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 N-(3-chlorophenyl)-6-(2-chloropyridin-4-yl)-[1,3,5]triazine-2,4-diamine
  参考文献：
  名称：

  [EN] SUBSTITUTED TRIAZINE KINASE INHIBITORS
  [FR] INHIBITEURS DES KINASES A BASE DE TRIAZINE SUBSTITUEE

  摘要：

  本发明提供了替代的1,3,5-三嗪化合物作为激酶抑制剂，并提供了一种治疗或改善激酶介导的疾病的方法。

  公开号：

  WO2004009562A1

文献信息

• [EN] N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS DE N,6-BIS(ARYL- OU HÉTÉROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE À TITRE D'INHIBITEURS DES MUTANTS IDH2 POUR LE TRAITEMENT DU CANCER
  申请人：AGIOS PHARMACEUTICALS INC

  公开号：WO2015006592A1

  公开（公告）日：2015-01-15

  Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.

  提供的是化合物的结构式（I），其中：环A和环B分别是可选择地取代的5-6成员单环芳基或杂环芳基。这些化合物是异柠檬酸脱氢酶2（IDH2）突变体的抑制剂，可用于治疗癌症。
• N,6-BIS(ARYL OR HETEROARYL)-1,3,5-TRIAZINE-2,4-DIAMINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：AGIOS PHARMACEUTICALS, INC.

  公开号：US20160158241A1

  公开（公告）日：2016-06-09

  Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.

  提供的化合物的化学式为（I），其中：环A和环B各自独立地是可选取代的5-6成员单环芳基或杂芳基。这些化合物是异柠檬酸脱氢酶2（IDH2）突变体的抑制剂，可用于治疗癌症。
• N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
  申请人：Agios Pharmaceuticals, Inc.

  公开号：US10111878B2

  公开（公告）日：2018-10-30

  Provided are compounds of formula (I), Wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl. The compounds are inhibitors of isocitrate dehydrogenase 2 (IDH2) mutants useful for treating cancer.

  提供了式(I)化合物 其中：环 A 和环 B 各自独立地为任选取代的 5-6 位单环芳基或杂芳基。这些化合物是异柠檬酸脱氢酶 2（IDH2）突变体的抑制剂，可用于治疗癌症。
• Synthesis and Identification of [1,3,5]Triazine-pyridine Biheteroaryl as a Novel Series of Potent Cyclin-Dependent Kinase Inhibitors
  作者：Gee-Hong Kuo、Alan DeAngelis、Stuart Emanuel、Aihua Wang、Yan Zhang、Peter J. Connolly、Xin Chen、Robert H. Gruninger、Catherine Rugg、Angel Fuentes-Pesquera、Steven A. Middleton、Linda Jolliffe、William V. Murray

  DOI：10.1021/jm040214h

  日期：2005.7.1

  On the basis of previous studies, we identified pyrazine-pyridine A as a potent vascular endothelial growth factor inhibitor and pyrimidine-pyridine B as a moderately potent cyclin dependent kinase (CDK) inhibitor. A proposed combination of CGP-60474 and compound B led to the discovery of [1,3,5]triazine-pyridine as a new series of potent CDK inhibitors. Palladium-catalyzed C-C bond formation reactions, particularly the Negishi coupling reaction, were used to assemble various triazine-heteroaryl analogues effectively. Among them, compound 20 displayed high inhibitory potency at CDK1 IC50 = 0.021 mu M), CDK2, and CDK5 and submicromolar potency at CDK4, CDK6, and CDK7. Compound 20 also displayed high potency at GSK-3 beta. It demonstrated potent antiproliferative activity on various tumor cell lines, including HeLa, HCT-116, U937, and A375. When 20 was administered intraperitoneally at 150 and 125 mg/kg to nude mice bearing human A375 xenografts, the compound produced a significant survival increase. Molecular docking studies were conducted in an attempt to enhance the understanding of the observed structure-activity relationship.
• SUBSTITUTED TRIAZINE KINASE INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：EP1546121B1

  公开（公告）日：2012-08-29